Death
Disease Event (e.g., relapse, failure to achieve remission)  To estimate the cost of treatment from using ATO in a 1st-line APL patient from the perspective of Italian national health system
Target Population Adult patients with newly diagnosed, low risk (based on a white blood cell count of <10,000) APL Comparators ATRA combined with idarubicin (AIDA) regimen -the only treatment regimen currently approved in Italy for 1st-line APL Time Horizon A three-year time horizon was utilized to encompass a full treatment cycle with either regimen, as well as align with Analyses were also conducted for both one-and two-year time horizons Model Structure A three-state Markov ("state-transition") model was developed depicting the natural history and outcomes of APL All patients begin in the "stable disease" health state and stay in this state while receiving their initial therapy until they experience a disease event or die  While pharmacy costs were higher for ATO than AIDA, non-pharmacy costs in all categories (including direct medical, AE treatment, and disease events) were lower for ATO patients over time:  Due to the lower risks of both disease events and AEs  Due to shorter treatment duration (8 months versus 28 months for AIDA) in ATO patients 5  Within the non-pharmacy medical cost component, induction and consolidation costs were lower in ATO patients  There were no maintenance costs (pharmacy or medical) in ATO patients  Further research is needed to determine the cost-effectiveness of ATO in the 1 st -line setting, especially in light new studies supporting better clinical and quality of life outcomes for APL patients when the treatment regimen does not contain conventional cytotoxic chemotherapy 5,7,9 -Patients who enter the disease event state discontinue their assigned treatment and begin 2nd-line chemotherapy in the next cycle -Patients can move to death from either the stable disease or disease event states  Efficacy data, including the definition of disease events, event-free survival, overall survival, and the probability of adverse events (AEs) were defined by the Lo-Coco (2013) multinational Phase III clinical trial 5  A one-month cycle length was chosen as this closely approximated the length of chemotherapy phases from the clinical trial  The schedule of pharmacy cost, direct medical costs, and AE probabilities derived from Lo-Coco (2013) is shown below in Table 1 5  Disease Events include: hematological or molecular relapse; failure to achieve hematological or molecular remission; death  Treatment-related AEs: neutropenia, thrombocytopenia, hepatic toxicity, fever of unknown origin (FUO) -Only AEs likely to impact treatment course or cause additional health-related costs were included Sensitivity Analysis  A one-way sensitivity analysis was performed to identify parameters with highest impact on treatment cost Base Case Default Parameters  The results were collected for a single hypothetical patient beginning the model in Year 1; efficacy parameters were calibrated using Microsoft Excel Solver© from EFS and OS curves in Lo-Coco (2013) 5
Limitations
 Costs of 2 nd -line treatment were not fully assessed (e.g., AEs and secondary survival were not included)  Only low risk patients are eligible for treatment with ATO 
Results
 ATO treatment costs for a single patient increased 25% from year 1 to year 2, followed by a 2% increase from year 2 to year 3  For AIDA, the increase from year 1 to year 2 was 15%, followed by 8% increase from year 2 to year 3  Expected pharmacy costs for the ATO regimen were higher than the AIDA regimen (see Table 5 )  Direct medical costs were over twice as much for AIDA compared to ATO (AIDA consolidation requires inpatient hospitalization)  AE costs and relapse costs were substantially higher for an AIDA patient (see Table 5 ) Sensitivity Analysis A total of 64 parameters were included in the deterministic sensitivity analysis (DSA) in the following categories: regimen costs, medical costs, AE probability, AE costs, efficacy (i.e., transition probabilities) 
